Societal CDMO Reports Inducement Grants for New Staff
SAN DIEGO and GAINESVILLE, Ga., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Societal CDMO, Inc. (“Societal CDMO”; NASD: SCTL), a contract...
News
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “the Company”), a...
Annexon Appoints Industry Veteran, Dr. Rick Artis, as Chief Scientific Officer to Support the Advancement and Expansion of Complement-focused Portfolio
BRISBANE, Calif., Jan. 06, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class...
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara®...
Alvotech and Teva Announce Acceptance of U.S. Biologics License Application for AVT04, a Proposed Biosimilar to Stelara® (ustekinumab)
The U.S. Food and Drug Administration’s (FDA) regulatory review is anticipated to be completed in the second half of 2023Stelara® (ustekinumab)...
Nicox: Half-year liquidity contract statement with Kepler Cheuvreux
Press Release Nicox: Half-year liquidity contract statement with Kepler CheuvreuxJanuary 6, 2023 – release at 7:30 am CETSophia Antipolis, France ...
FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma
If approved, glofitamab would be the first fixed-duration CD20xCD3 T-cell engaging bispecific antibody approved to treat the most aggressive type...
BioNTech Announces Strategic Partnership with UK Government to Provide up to 10,000 Patients with Personalized mRNA Cancer Immunotherapies by 2030
Multi-year collaboration focuses on three strategic pillars: cancer immunotherapies, infectious disease vaccines, and expansion of BioNTech’s footprint in the UKBioNTech...
MediGO Named to Inc.’s 2022 Best in Business List in Logistics and Transportation
3rd annual list recognizes 241 private companies putting purpose ahead of profitBALTIMORE, Jan. 05, 2023 (GLOBE NEWSWIRE) -- MediGO, a...
JenaValve Appoints Dan Dearen to Board of Directors
IRVINE, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of differentiated transcatheter aortic valve replacement...
Aerami Therapeutics to Present at Biotech Showcase™ 2023 during the 41st Annual J.P. Morgan Healthcare Conference Week
DURHAM, N.C., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Aerami Therapeutics (“Aerami”), a clinical stage biopharmaceutical company dedicated to breathing life...
AMN Healthcare Recognized by Newsweek as One of America’s Most Responsible Companies
DALLAS, Jan. 05, 2023 (GLOBE NEWSWIRE) -- AMN Healthcare, the nation’s leader and innovator in healthcare total talent solutions, has...
Qualigen Therapeutics Provides Update on Developments at NanoSynex; Significant Progress Reported on Infectious Disease Diagnostic Platform
CARLSBAD, Calif., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,” Nasdaq: QLGN), a diversified life...
Acasti to Host Conference Call on Tuesday, January 10, 2023 to Discuss Results from Recent Phase 1 PK Studies for GTX-101 and GTX-102 That Met All Outcome Measures
LAVAL, Québec, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in Pre-Clinical Trial
In a series of pre-clinical trials, Clearmind’s drug candidate MEAI significantly reduced body weight, improved fatty liver disease, and normalized...
SciSparc Ltd. Announces Efficacy of Psychedelic-Based Obesity Treatment of Clearmind Medicine Inc. in Pre-Clinical Trial
SciSparc and Clearmind’s collaboration continues to yield positive outcomes, the latest with Clearmind results for treating obesity and its related...
Carmot Therapeutics Launches Spin-Off, Kimia Therapeutics, to Focus on Metabolic Disease
– Spin-off of technology platform to newly-formed Kimia Therapeutics intended to maximize the full potential of Carmot’s metabolic portfolio while...
North Louisiana Forensic Science Center to host Cannabix Marijuana Breathalyzer Technology
Cannabix is developing Marijuana Breathalyzer devices to give law enforcement and employers a tool to enhance public safety Cannabix Technologies...
AIM ImmunoTech to Present at the ‘Virtual Investor 2023 Companies to Watch Event’
Live video webcast on Wednesday, January 18th at 11:00 AM ETOCALA, Fla., Jan. 05, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech...
TCR² Therapeutics Announces Pipeline Priorities for 2023
gavo-cel Phase 2 clinical trial now focused on ovarian cancer cohort with first meaningful durability data expected in 2H 2023Second-generation...